Want to join the conversation?
$CELG's selling, general and administrative expenses for 2015 increased by 13.7% from 2014. The rise was primarily due to rises in expenses from supporting inflammation and immunology products and product candidates, such as Otezla as well as rises in selling and marketing activities for Revlimid, Otezla and Pomalyst/Imnovid.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.